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Summary
Angiopoietin-2 (Ang2) exhibits broad expression in the remodeling vasculature of human tumors but very limited expression
in normal tissues, making it an attractive candidate target for antiangiogenic cancer therapy. To investigate the functional
consequences of blocking Ang2 activity, we generated antibodies and peptide-Fc fusion proteins that potently and selec-
tively neutralize the interaction between Ang2 and its receptor, Tie2. Systemic treatment of tumor-bearing mice with these
Ang2-blocking agents resulted in tumor stasis, followed by elimination of all measurable tumor in a subset of animals.
These effects were accompanied by reduced endothelial cell proliferation, consistent with an antiangiogenic therapeutic
mechanism. Anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis.
These results imply that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients
with solid tumors.
Introduction cancer therapy, such as drug resistance and inadequate drug
delivery, might be averted. Promising results have been ob-
Conventional cancer therapies often fail to control disease and served in clinical trials employing such agents (Hurwitz et al.,
are toxic by design. To avoid these drawbacks, pharmaceutical 2003; Kabbinavar et al., 2003; Raymond et al., 2002; Yang et
efforts are increasingly focusing on therapies that target molecu- al., 2002), particularly with drugs targeting the VEGF-VEGFR
lar abnormalities specific to tumorigenesis. While some success pathway, such as Bevacizumab (a humanized VEGF-A binding
has been achieved with such targeted drugs (e.g., STI571, Ritux- antibody that was recently approved for the treatment of colon
imab, Trastuzumab, Gefitinib, and Erbitux), none of the commer- cancer) and SU11248 (a small molecule that inhibits the activity
cially approved targeted therapies is capable of treating broad of several protein kinases, including KDR, a VEGF receptor).
populations of cancer patients (Rothenberg et al., 2003). More- Nonetheless, clinical efficacy has been mixed for drugs targeting
over, while the targeted therapies are generally less toxic than the VEGFs or their receptors (Anonymous, 2002; Miller et al.,
conventional cancer therapies, clinical safety issues have been 2002; Zangari et al., 2004), and significant toxicities have been
noted for these drugs. It has been proposed that antiangiogenic observed, including fatigue, headaches, hypertension, clotting
cancer therapy might be more broadly effective and safer than abnormalities, and life-threatening hemorrhages (DeVore et al.,
either targeted or traditional therapies aimed at cancer cells 2000; Kabbinavar et al., 2003; Miller et al., 2002).
(Folkman, 1998). Moreover, because antiangiogenic therapy is While the VEGFs and their receptors have been among the
designed to target blood vessels perfusing tumors, rather than most extensively targeted molecules in the angiogenesis field,
preclinical efforts targeting the more recently discovered angio-tumor cells themselves, traditional impediments to successful
S I G N I F I C A N C E
It has been proposed that therapies targeting the tumor vasculature may be more broadly efficacious and less toxic than conventional
cancer treatments. Rational design of such therapies involves the identification and characterization of candidate drug targets
whose functions are largely restricted to the process of angiogenesis. Ang2, a secreted factor whose expression is upregulated at
sites of angiogenesis, holds promise as one such candidate. To evaluate the in vivo effects of Ang2 neutralization, we have developed
Ang2-selective inhibitors. Systemic anti-Ang2 therapy inhibited tumor growth and angiogenesis in preclinical pharmacology models,
and it was well tolerated. Whether Ang2-selective inhibitors will mediate similar effects in humans awaits the evaluation of these
therapies in clinical trials.
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poietin-Tie2 pathway are now gaining strength (Qian et al., or Ang2 are playing pro- and/or antiangiogenic roles in this
context. Bolstering the hypothesis that Ang2 is proangiogenic,2002). Both protein families involve ligand-receptor interactions,
Ang2 knockout mice display early postnatal vascular remodelingand both include members whose functions are largely re-
defects in the eye (Gale et al., 2002; Hackett et al., 2002), asstricted postnatally to endothelial cells (and some hematopoietic
well as developmental lymphatic defects; curiously, the latterstem cell lineages [Iwama et al., 1993]) by virtue of the selective
deficiency, but not the former, can be rescued by replacing theexpression of their respective receptors on those cell types
Ang2 gene with the Ang1 gene. Blocking angiopoietin function(Gale and Yancopoulos, 1999; Mustonen and Alitalo, 1995). Tie2
pharmacologically in a postnatal setting by sequestration withis a receptor tyrosine kinase with four known ligands, angiopoie-
a soluble Tie2 receptor has been shown to have an inhibitorytin-1 (Ang1) through angiopoietin-4 (Ang4), the best studied
effect on tumorigenesis and neovascularization (Das et al., 2003;being Ang1 and Ang2 (Gale and Yancopoulos, 1999). Whereas
Hangai et al., 2001b; Lin et al., 1997, 1998; Siemeister et al.,Ang1 clearly stimulates phosphorylation of Tie2, Ang2 interac-
1999). However, given that all four angiopoietins bind to Tie2,tion with Tie2 has been shown to both antagonize and agonize
it is not clear whether this effect was mediated by inhibition ofTie2 receptor phosphorylation, under varying conditions (Davis
Ang1, Ang2, Ang3, Ang4, or a combination thereof. To enableet al., 1996; Kim et al., 2000; Maisonpierre et al., 1997; Mochizuki
a more definitive evaluation of postnatal Ang2 function, we haveet al., 2002; Teichert-Kuliszewska et al., 2001). The phenotypes
generated agents capable of selectively neutralizing the activityof mouse Tie2 and Ang1 knockouts are similar and suggest that
of this factor. Here, we show that systemic administration ofAng1-stimulated Tie2 phosphorylation mediates both remodel-
these Ang2-selective inhibitors is sufficient to suppress bothing and stabilization of developing vessels in utero through
tumor angiogenesis and corneal angiogenesis, thus supportingmaintenance of endothelial cell:support cell adhesion (Dumont
the notion that Ang2 plays a proangiogenic role postnatally.et al., 1994; Sato et al., 1995; Suri et al., 1996). The role of Ang1
in vessel stabilization is thought to be conserved in the adult,
Resultswhere the gene is expressed widely and constitutively (Hanahan,
1997; Zagzag et al., 1999). In contrast, normal postnatal Ang2
Identification and characterizationexpression is highest at sites of vascular remodeling (ovary,
of Ang2-selective inhibitorsplacenta, and uterus), where it has been proposed to block
Two types of Ang2-selective inhibitors, peptide-Fc fusion pro-Ang1 function, thereby inducing a state of vascular plasticity
teins and antibodies, were generated as reagents to interrogateconducive to angiogenesis (Hanahan, 1997; Holash et al., 1999;
angiopoietin function (Supplemental Experimental ProceduresMaisonpierre et al., 1997). Vessel-selective Ang2 induction has
at http://www.cancercell.org/cgi/content/full/6/4/507/DC1/). Phagealso been demonstrated in disease states associated with an-
display peptide and Fab libraries were panned against humangiogenesis. These pathological conditions include cancer, mac-
Ang2, and the resulting Ang2 binding clones were converted intoular degeneration, rheumatoid arthritis, osteoarthritis, and psori-
peptide-Fc fusion proteins (by expressing the active peptides inasis (Bunone et al., 1999; Etoh et al., 2001; Fearon et al., 2003;
E. coli as fusions to the Fc portion of human IgG1) or fully humanHangai et al., 2001a; Holash et al., 1999; Kuroda et al., 2001;
antibodies (by expressing the active Fabs in CHO cells on aOtani et al., 1999; Shahrara et al., 2002; Stratmann et al., 1998;
complete IgG1 framework). Peptide-Fc fusion proteins and anti-Tanaka et al., 1999; Yoshida et al., 1999; Yuan et al., 2000;
bodies were then screened by ELISA for their ability to neutralizeZagzag et al., 1999).
the interaction between Tie2 and angiopoietins. A subset of theElevated Ang2 expression at sites of normal and pathologi-
peptide-Fc fusion proteins were affinity-matured to enhancecal postnatal angiogenesis circumstantially implies a proangio-
their ability to neutralize Ang2. Two peptide-Fc fusion proteinsgenic role for Ang2 (Maisonpierre et al., 1997). However, experi-
(2xCon4 (C) and L1-7 (N)) and one antibody (Ab536) were chosenments designed to functionally confirm this conclusion have
for further study, based on their ability to potently neutralize the
yielded ambiguous and contradictory results. For example, ec-
human Ang2:human Tie2 interaction (IC50 values of 23, 54, andtopic expression of Ang2 in cancer cells has been shown to 140 pM, respectively [Table 1A]). All three reagents exhibited
promote tumor growth and vascularization in xenograft and similar IC50 values against Ang2 from other species (Table 1A),chorioallantoic membrane angiogenesis models (Ahmad et al., enabling their evaluation in preclinical pharmacology models.
2001; Etoh et al., 2001; Tanaka et al., 1999). In contrast, Ang2 Furthermore, the three inhibitors exhibited between 30-fold
overexpression has also been reported to inhibit both local tu- and 4500-fold selectivity for Ang2 over other angiopoietin
mor growth and metastasis and thereby prolong the survival of family members (Table 1A). Human IgG1 Fc alone exhibited no
mice injected with these tumors (Yu and Stamenkovic, 2001). angiopoietin-neutralizing activity in this ELISA. None of these
Experiments using transgenic mice ectopically expressing four agents had activity in a VEGF-VEGFR neutralization assay
VEGF, Ang1, and Ang2 in cardiac muscle have demonstrated (Table 1A), whereas Bevacizumab inhibited this interaction with
that Ang2 stimulates VEGF-mediated angiogenesis, whereas an IC50 of 2 nM (data not shown).
Ang1 suppresses it (Visconti et al., 2002). Further supporting To determine practical dosing frequencies and routes of
the hypothesis that Ang1 and Ang2 play mutually antagonistic administration for Ang2-blocking agents, pharmacokinetic pro-
roles in developmental vascular remodeling, Ang2 transgenic files were generated in rodents for 2xCon4 (C), L1-7 (N), and
mice (in which Ang2 expression is driven by the Tie2 promoter) Ab536 (Table 1B and Supplemental Experimental Procedures).
and Ang1 knockout mice share a similar phenotype, consisting The resulting pharmacokinetic parameters supported the feasi-
of defective vascular patterning, vessel discontinuity, and de- bility of daily to weekly subcutaneous dosing.
tachment of the endocardium from the myocardium (Maison-
pierre et al., 1997). But since this phenotype implies defects Ang2 antagonism inhibits tumor growth
in both vascular remodeling and stabilization, two seemingly To evaluate the effect of Ang2 inactivation on tumor growth,
nude mice bearing subcutaneous A431 human epidermoid tu-contradictory processes, it remains unclear whether either Ang1
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Table 1. Peptide-Fc fusion proteins and antibodies as competitive inhibitors of the angiopoietin:Tie2 interaction
hAng2 mAng2 rAng2 hAng1 mAng1 hAng4 mAng3 hVEGF
A: Agent IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
2xCon4 (C) 0.023 0.021 0.049 0.9 0.64 100 100 100
L1-7 (N) 0.054 0.071 0.160 100 100 100 100 100
Ab536 0.140 0.061 0.270 100 100 100 100 100
Fc 100 100 100 100 100 100 100 100
Mouse Rat
Dose-normalized Dose-normalized
AUCinf (nMhr/ AUCinf (nMhr/
B:
Agent t1/2 (hrs) mg/kg) t1/2 (hrs) mg/kg)
2xCon4 (C)a 97 15097 85 8733
L1-7 (N)a 56 6967 47 4637
Ab536b 83 3367 102 12702
A: Peptide-Fc fusion proteins, antibody, and human IgG1 Fc were evaluated by ELISA for their ability to neutralize angiopoietin:Tie2 interactions. Candidate
inhibitory agents were titrated from 100 nM to 0.4 pM in the presence of 1 nM Tie2 and subsequently added to a panel of angiopoietins. The degree of
angiopoietin:Tie2 neutralization (IC50) was determined by comparison against a Tie2 standard curve (the binding activity of serially diluted Tie2 in the
absence of competitor). As an additional control for specificity, Ang2-inhibitory agents were also tested in an analogous fashion for their ability to neutralize
the hVEGF:KDR interaction (last column of table). Bevacizumab (a neutralizing anti-hVEGF antibody) displayed a 2.1 nM IC50 in this assay (data not shown).
B: Pharmacokinetic parameters of Ang2 inhibitors in mice and rats. Terminal half-lives (t1/2) and areas under the serum concentration-time curves from time
0 to infinity (AUCinf) are shown. AUCinf values were normalized to a 1 mg/kg dose.
a t1/2 and AUCinf were calculated from the composite mean serum concentration-time data, n  2–3/time point.
b t1/2 and AUCinf were calculated from the mean serum concentration-time data of 6 mice or 3 rats.
mor xenografts were treated with a range of Ab536 dose levels that the effects of Ab536 on tumor growth in vivo were conferred
indirectly through an antiangiogenic mechanism, rather than(thrice weekly) beginning 3 days after tumor challenge (Figure
1A). A431 xenografts, like other tumor models, display vessel- through a direct effect on tumor cells.
We next sought to determine whether the tumor growthselective Ang2 expression (Figure 1C and Supplemental Experi-
mental Procedures). Ab536 significantly inhibited tumor growth inhibition observed in the A431 model could be reproduced in
other tumor models. Administration of 2xCon4 (C), L1-7 (N), orrelative to control IgG when dosed at 2 and 6 mg/kg, but not
at lower dose levels (Figure 1A). A longer-term study employing Ab536 to mice bearing subcutaneous Colo205 human colorectal
tumor xenografts resulted in tumor growth inhibition, indicatingAb536 at 2 mg/kg (the optimal biological dose) showed more
dramatic inhibition of tumor growth (Figure 1B). Ab536, as well that the observed antitumor effects were not cancer type spe-
cific or reagent specific (Figure 2A). Vascular Ang2 expressionas the other Ang2 inhibitors, failed to suppress the growth of
cultured A431 cells (Figure 1D), consistent with the hypothesis was confirmed by in situ hybridization (Figure 2B and Supple-
Figure 1. Effect of anti-Ang2 agents on the
growth of A431 tumor xenografts and cultured
A431 tumor cells
A and B: Inhibition of A431 tumor xenograft
growth with a systemically administered Ang2-
neutralizing agent. Treatment was initiated 3
days postinjection of tumor cells. Ab536 was
dosed thrice weekly.
C: Paired brightfield and darkfield images of
Ang2 in situ hybridization, demonstrating Ang2
mRNA expression in endothelial cells lining a
blood vessel within the mass of an A431 tumor
xenograft from an untreated animal. The hori-
zontal bar indicates scale.
D: In vitro growth of A431 cells in the presence
of Ang2 inhibitors. Cells were seeded in 96-well
plates and treated with the indicated concen-
trations of human Fc, human IgG, L1-7 (N),
2xcon4 (C), and Ab536. Cells were fixed and as-
sayed at 24, 48, 72, 96, and 120 hr of treatment.
CANCER CELL : NOVEMBER 2004 509
A R T I C L E
Figure 2. Effect of anti-Ang2 agents on the
growth of Colo205 tumor xenografts
A: Inhibition of Colo205 tumor xenograft growth
with systemically administered Ang2-neutralizing
agents. Treatment was initiated 3 days postinjec-
tion of tumor cells.
B: Paired brightfield and darkfield images of
Ang2 in situ hybridization, demonstrating Ang2
mRNA expression in endothelial cells lining a
blood vessel within the mass of a Colo205 tumor
xenograft from an untreated animal. The hori-
zontal bar indicates scale.
mental Experimental Procedures). Ang2 inhibition was shown Even more dramatic regression, apparent even by gross
external measurements, was observed when the initiation ofto mediate similar tumor growth inhibition in the HT29 xenograft
model (Supplemental Figure S1). therapy was further delayed, and this regression appeared to
be reversible following serum clearance of the Ang2-neutralizingTwo additional Colo205 tumor xenograft experiments were
performed to evaluate peptide-Fc fusion protein dose-response agent (Figure 5). In this experiment, 2xCon4 (C) was adminis-
tered on either a twice weekly schedule (0.6 mg/kg) startingrelationships. Twice weekly administration of 0.6 or 15 mg/kg
2xCon4 (C) yielded equivalent levels of tumor growth inhibition on Day 21 (“narrow-interval dosing”) or in individual doses (25
mg/kg) on Days 45 and 116 (“wide-interval dosing”). Dosing on(Figure 3A), whereas dosing of 0.12 or 0.024 mg/kg 2xCon4 (C)
on the same schedule resulted in a progressive reduction in a wide interval allowed 2xCon4 (C) to be cleared from the serum
between doses. Rapid tumor regression was observed in theeffect relative to the 0.6 mg/kg dose (Figure 3B). The same
optimal biological dose of 0.6 mg/kg twice weekly was observed wide-interval group following the Day 45 dose. This regression
was sustained until Day 69, at which point tumor regrowth beganwith L1-7 (N) (data not shown).
In the tumor xenograft studies discussed thus far, dosing to occur, suggesting that 2xCon4 (C) exposure had fallen below
effective levels. Resumption of dosing on Day 116 resulted againbegan 3 days after tumor cells were injected. To better replicate
conditions of established disease, Colo205 tumors were al- in tumor regression, indicating that tumors had not acquired
resistance to anti-Ang2 therapy. While this study showed revers-lowed to grow for 28 days before 2xCon4 (C) dosing was initi-
ated (Figure 4A). A separation in growth rates between the vehi- ibility of the treatment-mediated antitumor effect, growth inhibi-
tion was not observed to be reversible in experiments in whichcle and treated groups could be observed within 3 days of
treatment initiation, and the gross tumor volume of the treatment dosing was initiated by experimental Day 28 (data not shown).
To further evaluate the long-term effects of Ang2 inhibitiongroup remained static over the 21 days of therapy, indicating
that anti-Ang2 therapy could inhibit the growth of established on tumor growth, several groups of animals harboring A431
and Colo205 tumor xenografts were treated continuously withtumors. To examine drug effects at the histological level, cohorts
of animals in this study were sacrificed weekly for tumor evalua- 2xCon4 (C) or Ab536 for at least 10 weeks (Supplemental Table
S1 and Supplemental Experimental Procedures). Although vari-tion. A progressive reduction in viable tumor fraction was ob-
served in the treatment group relative to the vehicle group (Fig- ous dosing levels and schedules were employed, all were pre-
dicted to result in serum trough levels exceeding the exposureures 4B–4D and Supplemental Experimental Procedures),
indicating that volume-based tumor measurements, which fail required for optimal effect. In 13 of 15 groups, anti-Ang2 therapy
eliminated all measurable tumor in a subset of animals. In threeto distinguish viable tumor from necrotic tissue, underestimated
peptide-Fc fusion protein-mediated antitumor effects. Thus, of these groups, drug was withdrawn after the complete re-
sponses were achieved, and no tumor regrowth was observedanti-Ang2 treatment mediated regression of viable tumor.
Figure 3. Dose-response effect of systemically
administered 2xCon4 (C) in the Colo205 xeno-
graft model
A: 2xCon4 (C) dose levels of 15 and 0.6 mg/kg
(twice weekly) had similar antitumor effects to
one another and to Ab536 dosed at 2 mg/kg
(thrice weekly).
B: Reducing the 2xCon4 (C) doses levels to 0.6,
0.12, and 0.024 mg/kg (twice weekly) resulted
in a clear dose-response effect. While maximal
effect was observed with 0.6 mg/kg, a partial
inhibitory effect was observed with the interme-
diate dose of 0.12 mg/kg. The low dose of 0.024
mg/kg was ineffective.
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Figure 4. Effect of 2xCon4 (C) treatment on viable tumor fraction in the Colo205 xenograft model
A: Mice were treated twice weekly with 15 mg/kg 2xCon4 (C) starting on day 28 postinjection of Colo205 tumor cells. Tumors were harvested at different
time points following treatment initiation for the histological analysis described below. Representative tumor volumes from mice treated with 2xCon4 (C)
or vehicle for 21 days are shown.
B: Analysis of tumor viable area fraction comparing 2xCon4 (C)-treated mice and vehicle-treated mice. Eight tumors per group were measured on
posttreatment days 0, 7, 14, and 21. A significant reduction in tumor viability was demonstrated following 7 days of 2xCon4 (C) treatment.
C and D: Representative hematoxylin-stained histological sections of bisected tumors following 21 days of treatment with vehicle or 2xCon4 (C), respectively.
The horizontal bars indicate scale.
in these animals (average follow-up 15.3 weeks; range 6–27 systems attributable to Ang2 neutralization (Supplemental Ex-
weeks). perimental Procedures). The 2xCon4 (C) protein had no signifi-
Upon completion of tumor xenograft studies, mice were cant adverse effects on xenograft-bearing mice when dosed
sacrificed to search for possible adverse effects in major organ either at 14 mg/kg twice per week for 11 weeks (monitoring
hematology values, serum chemistry values, or histology) or 8
mg/kg daily for 11 weeks (monitoring organ weights and histol-
ogy). Similarly, L1-7 (N) had no untoward effects on any of the
endpoints evaluated (hematology values, serum chemistry, or
histology) in xenograft-bearing mice when dosed at 14 mg/kg
twice per week for 7 weeks.
Ang2 inhibition suppresses the proliferation
of tumor endothelial cells
To begin investigating the mechanism through which Ang2 neu-
tralization mediates tumor growth inhibition, Colo205 xenografts
from mice treated with 2xCon4 (C) or vehicle were evaluated
at the cellular level. FACS analysis revealed that 2xCon4 (C)
treatment resulted in a progressive reduction in endothelial cell
proliferation, followed by a reduction in tumor cell proliferation
(Figure 6A and Supplemental Experimental Procedures), sug-
Figure 5. Systemically administered 2xCon4-C induces regression of large gesting that the 2xCon4 (C)-mediated antitumor effects oc-
established tumors curred secondary to a drop in tumor perfusion. That is, while
One group of mice was treated twice weekly with 15 mg/kg 2xCon4 (C) 24 hr of 2xCon4 (C) treatment was sufficient to inhibit endothelial
beginning on Day 21 postinjection of cells (“Narrow-Interval Dosing” group). cell proliferation, 72 hr of 2xCon4 (C) treatment was required
The other group was treated with vehicle until Day 44 and then with
to achieve a reduction in tumor cell proliferation that deviated25 mg/kg doses of 2xCon4 (C) on Days 45 and 116 (“Wide-Interval Dosing”
group). below the aggregate mean tumor cell proliferation of all vehicle-
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Figure 6. Cel l-based mechanism-of-action
studies
A: Effect of 2xCon4 (C) on BrdU uptake in tumor
cells and endothelial cells derived from Colo205
xenografts. Tumor-bearing mice were treated
with a single dose of 15 mg/kg 2xCon4 (C) or
vehicle at study day 28. Tumors were collected
at different times posttreatment and digested
enzymatically, and cells were extracted for FACS
analysis. 18 hr prior to each tumor harvest, mice
were implanted subcutaneously with osmotic
minipumps (Zymed Labs 2001D, 8 l/hr, 1 day)
containing 3 mg/ml BrdU. Dissociated cells
were stained with anti-mouse CD45-FITC and
CD31-PE antibodies, followed by fixation and
staining with anti-BrdU-alexa647 antibodies. En-
dothelial cell (CD45/CD31 mouse diploid pop-
ulation) and tumor cell (CD45/CD31/FSC tet-
raploid population) BrdU uptake was normalized
to total diploid mouse cell BrdU uptake for each tumor sample. The bar graph represents normalized mean BrdU ratios (n  4, except for 72 hr vehicle
group [n  1] and 72 hr 2xCon4 group [n  2]).
B: Apoptotic tumor cell counts per 20 objective field (135,600 m2), comparing 2xCon4 (C)-treated and vehicle-treated mice. Eight tumors per group
were evaluated following 1, 2, or 3 days of treatment. This analysis demonstrated a significant increase in tumor cell apoptosis following 2 days of 2xCon4
(C) treatment.
treated groups (tumor cell proliferation in the vehicle-treated was well tolerated and revealed no significant adverse effects
(Supplemental Experimental Procedures). A pharmacologicalgroups remained relatively constant over time). Additional analy-
ses by histological methods demonstrated that 2xCon4 (C) in- effect on epiphyseal growth plate thickness was observed in
male 2xCon4 (C)-treated rats dosed at 75 mg/kg (2 of 3 rats)duced tumor cell apoptosis in Colo205 xenografts (Figure 6B),
an effect that is consistent with the reduced viable tumor fraction and 200 mg/kg (3 of 3 rats). No growth plate abnormalities
were observed in identically treated rats that were subsequentlyobserved in 2xCon4 (C)-treated mice (Figures 4B–4D). The tem-
poral and causative relationships between 2xCon4 (C)’s effects withdrawn from drug for 1 month, suggesting that these effects
on tumor cell proliferation and apoptosis are not yet known. were reversible. Epiphyseal plate thickening is considered to
be a pharmacological consequence of antiangiogenic therapy
Direct antiangiogenic effect mediated and has been seen in growing rodents treated with VEGF-neu-
by Ang2 neutralization tralizing antibodies (Gerber et al., 1999). This phenomenon
We next sought further support for the hypothesis that anti- would not be expected to occur in adult animals treated with
Ang2 therapy mediates a direct antineovascular effect in vivo. antiangiogenic agents, as endochondral bone formation is com-
The rat corneal angiogenesis model was chosen for this pur- pleted before adulthood. Also of note, a multifocal infiltration
pose, as it allows neovascularization to be studied outside the of mononuclear cells was seen on the exterior surface of the
context of tumorigenesis. In this model, a VEGF-soaked nylon splenic capsule in some treated rodents, but not primates (data
disk is placed in the normally avascular cornea at a fixed dis- not shown). The finding had no known functional consequences,
tance from the surrounding limbal vessels. Neovessels subse- and its etiology is under investigation. Together, the accumu-
quently sprout from the limbal vessels toward the developing lated preclinical pharmacology data support the conclusion that
VEGF gradient. In situ hybridization (ISH) was used to demon- Ang2 inactivation suppresses angiogenesis in both neoplastic
strate that Ang2 was expressed in the VEGF-induced corneal and nonneoplastic settings, without untoward effects on animal
neovasculature (Supplemental Figure S2 and Supplemental Ex- health.
perimental Procedures). Ang2 mRNA levels were shown to be
upregulated during VEGF-induced corneal angiogenesis in a Discussion
punctate pattern similar to that observed in tumor vessels. Ang2
ISH signal was identified only in neovessels sprouting from the Previous work in this field has highlighted the complexity of
Ang2 function. In vitro and in vivo experiments have suggestedlimbus, and no signal could be observed in the absence of
exogenous VEGF stimulation. The consequences of inactivating that Ang2 can either agonize or antagonize (Davis et al., 1996;
Kim et al., 2000; Maisonpierre et al., 1997; Mochizuki et al., 2002;Ang2 in this model were then evaluated. Systemic administra-
tion of 2xCon4 (C) over a range of 0.125 to 4 mg/kg twice weekly Teichert-Kuliszewska et al., 2001) the Tie2 receptor, depending
on context. Ang2 has been shown to play opposing roles at theresulted in a dose-dependent inhibition of VEGF-mediated cor-
neal angiogenesis (Figure 7A), with reduction of angiogenesis cellular and organismal levels as well, promoting either vascular
sprouting or regression, depending on whether VEGF is presentto negative control levels observed at the 1 mg/kg dose level.
L1-7 (N) and Ab536 were also shown to inhibit corneal angiogen- (Maisonpierre et al., 1997). The phenotype of the recently pub-
lished Ang2 knockout mouse is informative in that it convincinglyesis to background levels (Figure 7B), further demonstrating
that the effects of anti-Ang2 therapy were not reagent specific. implicates Ang2 as a required factor for early postnatal retinal
neovascularization (Gale et al., 2002; Hackett et al., 2002). How-Treatment of rats with L1-7 (N) and 2xCon4 (C) at subcutane-
ous doses as high as 200 mg/kg twice weekly for 2 weeks ever, these studies also highlight the context-dependent nature
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Figure 7. Ang2 antagonists inhibit VEGF-induced
corneal angiogenesis
Angiogenesis was induced by implanting VEGF-
or BSA-soaked nylon discs into the corneal
stroma of female CD rats. Treatment with
2xCon4(C) (A), Fc control or L1-7(N) (B) was initi-
ated 1 week prior to corneal implantation and
continued twice per week. Animals receiving
Ab536 (B) were injected on the day of surgery
and three days later. For all groups, angiogenesis
was evaluated 1 week after disc implantation.
Values are the group mean  standard error of
the mean (n  8). *p  0.02.
of Ang2 dependency in angiogenesis; Ang2 was shown in these phenotype (Gale et al., 2002), in which no prenatal vascular
defects were observed, despite strong embryonic expressionsame experiments to be dispensable for developmental neovas-
cularization and for pathological angiogenesis in the abnormally of Ang2 in and around large vessels in wild-type mice. Thus,
expression of Ang2 does not necessarily confer functional de-retained hyaloid vasculature of rare knockout mice surviving
to day 25 (Gale et al., 2002). In tumor models, ectopic Ang2 pendence on this factor. Nonetheless, additional studies of
longer duration and in the context of other angiogenesis-associ-expression has been shown to both stimulate and inhibit tumor
growth and tumor angiogenesis, thus adding to the confusion ated processes (such as wound healing and estrous cycling)
would be necessary to fully assess the effects of Ang2-neutraliz-regarding Ang2 function. The only published attempt to selec-
tively neutralize Ang2 in vivo using a pharmacological agent (an ing agents.
While this study sheds light on Ang2 biology and the thera-RNA aptamer) resulted in incomplete angiogenic inhibition, even
in the context of local administration, thus leaving unanswered peutic implications of Ang2 inhibition, it also stimulates addi-
tional questions. First, the cellular and molecular consequencesthe question of whether Ang2 inhibition alone is sufficient to fully
inhibit angiogenesis (White et al., 2003). The cellular mechanism of Ang2 neutralization require further investigation. It remains
to be determined, for example, how Ang2 neutralization blocksthrough which selective Ang2 inhibition mediated angiogenic
suppression also remains to be addressed. Panangiopoietin endothelial cell proliferation, if it alters pericyte/cell matrix cover-
age of capillaries, or how it might alter tumor perfusion. Ofinhibition (with soluble Tie2) has also been shown to mediate
suppression of tumor growth and angiogenesis, but none of note, ectopically administered Ang2 has been shown to promote
endothelial cell proliferation and sprouting of new blood vesselsthese effects can be attributed specifically to Ang2 inactivation
(Das et al., 2003; Hangai et al., 2001b; Lin et al., 1997, 1998; in the papillary membrane of the eye, and these effects were
associated with increased capillary diameter, basal lamina re-Siemeister et al., 1999). It therefore remains unclear exactly
what molecular, cellular, and phenotypic roles Ang2 plays in modeling, and enhanced endothelial cell migration (Lobov et
al., 2002). It is attractive to consider that these same associatedpostnatal life in normal or pathological vascular processes, and
particularly in the setting of cancer. characteristics might be oppositely affected by Ang2 inhibition.
At the molecular level, it remains unclear how Ang2 neutraliza-To begin investigating this question, we generated Ang2-
selective peptide-Fc fusion proteins and antibodies, enabling tion affects Tie2 phosphorylation in individual vessels. Attempts
to address this question by immunohistochemistry using anti-controlled pharmacological inactivation of endogenous Ang2.
This approach to Ang2 inhibition circumvents the neonatal le- phospho-Tie2 antibodies have not been successful, as the re-
agent antibodies generated for this purpose have not been suf-thality observed in Ang2 knockout studies (Gale et al., 2002)
and avoids the ambiguous interpretations inherent in studies ficiently sensitive. Evaluating this question in a physiologically
relevant setting is critical to elucidating the true biochemicalusing panangiopoietin inhibitors (Das et al., 2003; Hangai et al.,
2001b; Lin et al., 1997, 1998; Siemeister et al., 1999). Our studies role of Ang2.
A second question that remains to be addressed is whetherdemonstrate that specific inactivation of endogenous Ang2 in-
hibits tumor angiogenesis in mice and corneal angiogenesis in selective inhibition of Ang1 would be advantageous or deleteri-
ous in terms of efficacy and safety. If, for example, Ang1 andrats, thus establishing that Ang2 plays a proangiogenic role in
these processes. A combination of volume-based tumor mea- Ang2 were both capable of stimulating tumor angiogenesis,
then greater tumor growth inhibition might be achievable bysurements and histological analysis indicate that selective Ang2
inhibition mediates regression of viable tumor. Moreover, a sub- neutralizing both angiopoietins, rather than inhibiting Ang2
alone. Alternatively, if Ang1 and Ang2 function in a mutuallyset (20%) of tumor-bearing mice completely responded to
long-term anti-Ang2 therapy, in that no residual tumor could be antagonistic manner, then selective Ang1 neutralization might
actually stimulate tumor growth. From the standpoint of safety,measured. This result suggested that even established tumor
vessels have the capacity to respond to Ang2 inhibition. one might predict, a priori, that Ang1 inhibition could globally
destabilize normal quiescent blood vessels, as Ang1 appearsNo significant adverse effects were observed in rodents
following long-term Ang2 inhibition, despite clear Ang2 expres- to play a role in normal vessel maintenance. Systemically admin-
istered soluble Tie2 has been reported to be efficacious andsion by ISH in several organs of 10-week-old mice (data not
shown). This result is reminiscent of the Ang2 knockout mouse safe in tumor models (Lin et al., 1998), but interpretation of
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and degree of VEGF:KDR neutralization was determined by comparisonthese studies is confounded by the fact that Ang1 and Ang2
against a KDR-Fc standard curve.inhibition could not be evaluated in isolation. While 2xCon4(C)
selectively inhibits Ang2, it too displays some inhibitory activity
Pharmacology studies
against Ang1. Despite this Ang1-neutralizing activity, 2xCon4(C) 8- to 10-week-old female CD1 nude mice (Charles Rivers Laboratories) were
shares a similar response profile with the more Ang2-selective used in all studies. Mice were injected subcutaneously with 0.2 ml of tumor
reagents (L1-7(N) and Ab536) evaluated herein, suggesting that cell suspension in RPMI, containing 1  107 A431 cells (ATCC), 2  106
Colo205 cells (ATCC), or 5  106 HT29 cells mixed with 2:1 volumes matri-(1) Ang2 may be the dominant angiopoietin in promoting postnatal
gel:cells (BD Bioscience). Subconfluent cells were harvested prior to injec-angiogenesis and (2) inhibiting Ang1 may confer no deleterious
tion. Treatment with peptide-Fc fusion proteins, antibodies, or vehicle (PBS)effects. Nonetheless, definitive evaluation of the consequences
was initiated as early as 3 days and as late as 45 days postinjection of
of inhibiting Ang1 awaits the generation of high-potency Ang1- cells. Peptide-Fc fusion proteins were administered subcutaneously, and
selective inhibitors and has implications for pharmaceutical strate- antibodies were administered intraperitoneally at the indicated doses and
gies involving targeted inactivation of the angiopoietins or their schedules. Tumor volumes and body weights were recorded at regular inter-
vals. Tumor volume was calculated as length  width  height in mm3.receptor.
Results are expressed in mean  standard error. The data were statisticallyA final question involves determining the clinical value of
analyzed with factorial ANOVA followed by Scheffe’s post hoc analysis forselectively inhibiting Ang2. Ang2 upregulation has been ob-
repeated measurements (StatView v5.0.1, SAS Institute). Mice were euthan-
served not only in cancer, but also in macular degeneration, ized with CO2 asphyxiation, and in some experiments tumors were collected
rheumatoid arthritis, osteoarthritis, and psoriasis (Bunone et al., and fixed for histological analysis. All experiments were conducted in accor-
1999; Etoh et al., 2001; Fearon et al., 2003; Hangai et al., 2001a; dance with institutional guidelines, which include mandates for sacrificing
mice when tumors exceed size thresholds.Holash et al., 1999; Kuroda et al., 2001; Otani et al., 1999;
Shahrara et al., 2002; Stratmann et al., 1998; Tanaka et al.,
In vitro cell growth assay1999; Yoshida et al., 1999; Yuan et al., 2000; Zagzag et al.,
A431 cells were seeded in 96-well tissue culture plates at 2000 cells per1999), suggesting that an effective Ang2 inhibitor might have
well in 200 l of DMEM supplemented with 10% fetal bovine serum (FBS).
wide applicability in treating human disease. Whether Ang2- 16 hr postseeding, the medium was replaced with 100 l per well of fresh
selective inhibitors will confer similar activity in humans to that DMEM/10% FBS containing 6.7 M Ang2-neutralizing agents or controls
observed in rodent models awaits the introduction of these (all in triplicate). Cells were fixed at 24, 48, 72, 96, and 120 hr post treatment
by adding 100 l 10% trichloroacetic acid (TCA). All plates were stored inagents into clinical trials.
10% TCA at 4C and assayed together. The 10% TCA was shaken out, and
the wells were rinsed 5 times with water. The cells were then stained withExperimental procedures
100 l of 0.4% sulforhodamine B (Sigma S-9012) in 1% acetic acid (Sigma
A-6283) for 10 min at room temperature and then washed 5 times with 1%Angiopoietin:Tie2 neutralization ELISA
acetic acid. The plates were then air-dried. The dye was solubilized with96-well microtiter plates were coated with recombinant angiopoietins in
300 l of 20 mM unbuffered Tris (pH  10) for 2 hr on a rotary shaker.293T cell conditioned media (DMEM/50 g/ml BSA) at 37	C for 1 hr. The
Optical density (OD) was then read at 540 nm on a microtiter plate reader.conditioned media were used at angiopoietin concentrations that conferred
75% of maximally achievable binding to 1 nM hTie2-Fc (R&D Systems,
Tumor cell apoptosis assaycatalog #313-TI). Plates were washed with PBS/0.1% Tween-20 and then
Tumor cell apoptosis was examined at days 1, 2, and 3 for both 2xCon4blocked for 2 hr at room temperature with PBS/5% BSA. Peptide-Fc fusion
(C)-treated and vehicle-treated controls, from the same study as the Viableproteins and antibodies titrated from 100 nM to 0.4 pM in a solution of PBS/
Tumor Fraction analysis. Sections were stained for cleaved Caspase-3 (Cat#-1% BSA/1 nM Tie2 were added to the angiopoietin-coated plates, which
Asp175, Cell Signaling Technologies) using peroxidase localization with DABwere incubated overnight at room temperature and then washed with PBS/
substrate, and a light hematoxylin counterstain. Five widely spaced fields0.1 percent Tween-20. Mouse-derived anti-Tie2 antibody (Pharmingen Inc.,
were selected in a blinded fashion from the circumferential region of eightcatalog #557039) was added to each plate at a final concentration of 1
tumor sections per group, avoiding the overlying capsule and areas of frankg/ml (1 hr incubation at room temperature), after which plates were washed
necrosis. The number of apoptotic tumor cells was counted in each 20in PBS/0.1% Tween-20. Goat anti-mouse-IgG-HRP (Pierce, catalog #31432)
objective field of roughly 135,600 m2.was added at a dilution of 1:10,000 in PBS/1% BSA (1 hr incubated at room
temperature), after which plates were washed several times with PBS/0.1%
Corneal angiogenesis modelTween-20. TMB substrate (Sigma, catalog #T8665) was added, OD 370 nm
Corneal angiogenesis was induced in adult female CD rats weighingabsorbance was measured, and degree of angiopoietin:Tie2 neutralization
250–300 g (n  8 per group) as described (Coxon et al., 2002). Briefly, 0.6was determined by comparison against a Tie2 standard curve.
mm diameter circular discs of Nyalflo filter paper (Gelman, Ann Arbor, MI)
were incubated in PBS containing either 0.1% bovine serum albumin (BSA)VEGF/KDR neutralization ELISA
96-well microtiter plates were coated with recombinant human VEGF (0.1 ml or 0.1% BSA with 10 M vascular endothelial growth factor (VEGF) (R&D
Systems, Minneapolis, MN) for 1 hr at 4	C. Rats were anesthetized withper well of 5 g/ml hVEGF in PBS/1% BSA) at 37	C for 1 hr. The recombinant
VEGF was used at concentrations that conferred 80% of maximally achiev- isoflurane and a single disc was inserted into a pocket in the corneal stroma.
The margin of each disc was located 1.8 mm from blood vessels of theable binding to 1 nM human KDR-Fc (R&D Systems, catalog #357-KD/CF).
Plates were washed with PBS/0.1% Tween-20 and then blocked for 2 hr lateral limbus.
Treatment with 2xCon4 (C) (0, 0.03, 0.1, 0.3, 1.0, or 10 mg/kg), Fcat room temperature with PBS/5% BSA. Peptide-Fc fusion proteins and
antibodies titrated from 1000 nM to 0.5 pM in a solution of PBS/1% BSA/ control (70 nM/kg), L1-7(N) (70 nM/kg), or vehicle (PBS) was initiated 1 week
prior to corneal implantation and continued twice per week. Rats treated1 nM KDR-Fc were added to the VEGF-coated plates, which were incubated
overnight at room temperature and then washed with PBS/0.1% Tween-20. with Ab536 (Ab536 0.7 or 70 nM/kg) received one injection on the day of
surgery and another 3 days later. All treatments were injected subcutane-Mouse-derived anti-KDR antibody (R&D Systems, catalog #MAB3573) was
added to each plate at a final concentration of 1 g/ml (1 hr incubation at ously.
7 days after surgical implant, the corneas were photographed at 25room temperature), after which plates were washed in PBS/0.1% Tween-20.
Goat anti-mouse-IgG-HRP (Pierce, catalog #31432) was added at a dilution using a Nikon SV-3 Ophthalmic Slit Lamp (Nikon Ophthalmic) equipped
with a Nikon D-1 digital camera back. A reference stage micrometer wasof 1:5000 in PBS/1% BSA (1 hr incubated at room temperature), after which
plates were washed several times with PBS/0.1% Tween-20. TMB substrate photographed for calibration. Numerical data were generated from the digital
images using Metamorph image analysis software (v4.5; Universal Imaging,(Sigma, catalog #T8665) was added, OD 370 nm absorbance was measured,
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Gale, N.W., Thurston, G., Hackett, S.F., Renard, R., Wang, Q., McClain, J.,Downingtown, PA). For each corneal image, the number of vessels inter-
Martin, C., Witte, C., Witte, M.H., Jackson, D., et al. (2002). Angiopoietin-2secting the midpoint between the disc and the limbus was measured. Values
is required for postnatal angiogenesis and lymphatic patterning, and onlyrepresent the group mean  standard error of the mean. Statistical signifi-
the latter role is rescued by angiopoietin-1. Dev. Cell 3, 411–423.cance was assessed by analysis of variance followed by Fisher’s exact test.
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